Uniqure NV
QURE
View Detailed Chart
14.770USD
-0.830-5.32%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
248.06MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.32%
5 Days
-8.20%
1 Month
-5.50%
6 Months
-75.13%
Year to Date
-38.28%
1 Year
+18.44%
View Detailed Chart
TradingKey Stock Score of Uniqure NV
Currency: USD Updated: 2026-03-27Key Insights
Uniqure NV's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 63 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.08.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Uniqure NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Uniqure NV Highlights
StrengthsRisks
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.10M.
Undervalued
The company’s latest PE is -4.27, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 59.61M shares, decreasing 3.63% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 74.04K shares of this stock.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
37.083
Target Price
+137.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Uniqure NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Uniqure NV Info
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Ticker SymbolQURE
CompanyUniqure NV
CEOKapusta (Matthew)
Websitehttps://www.uniqure.com/
Related Instruments
-2.10%
-1.92%
+0.49%
+2.48%
+0.58%
-0.88%
-0.98%
-1.24%
-0.51%
-1.96%
-1.02%
+0.34%
-0.19%
-1.55%
-4.56%
0.00%
-0.55%
-2.51%
-2.86%
-0.83%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
67618.070
+1034.020 (+1.55%)
275.340
+1.990 (+0.73%)
2067.070
+67.070 (+3.35%)
361.830
-10.280 (-2.76%)
4557.580
+65.060 (+1.45%)
100.392
-0.217 (-0.22%)
1.148
-0.002 (-0.18%)
159.518
-0.734 (-0.46%)
